- Home
- KTF vs DSGN Comparison
KTF vs DSGN Comparison
Compare KTF & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTF
- DSGN
- Stock Information
- Founded
- KTF 1988
- DSGN 2017
- Country
- KTF United States
- DSGN United States
- Employees
- KTF N/A
- DSGN N/A
- Industry
- KTF Finance Companies
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- KTF Finance
- DSGN Health Care
- Exchange
- KTF Nasdaq
- DSGN Nasdaq
- Market Cap
- KTF 384.3M
- DSGN 353.9M
- IPO Year
- KTF N/A
- DSGN 2021
- Fundamental
- Price
- KTF $9.47
- DSGN $6.25
- Analyst Decision
- KTF
- DSGN Hold
- Analyst Count
- KTF 0
- DSGN 3
- Target Price
- KTF N/A
- DSGN $7.00
- AVG Volume (30 Days)
- KTF 103.3K
- DSGN 208.4K
- Earning Date
- KTF 01-01-0001
- DSGN 11-07-2024
- Dividend Yield
- KTF 3.54%
- DSGN N/A
- EPS Growth
- KTF N/A
- DSGN N/A
- EPS
- KTF 0.39
- DSGN N/A
- Revenue
- KTF N/A
- DSGN N/A
- Revenue This Year
- KTF N/A
- DSGN N/A
- Revenue Next Year
- KTF N/A
- DSGN N/A
- P/E Ratio
- KTF $23.10
- DSGN N/A
- Revenue Growth
- KTF N/A
- DSGN N/A
- 52 Week Low
- KTF $7.40
- DSGN $2.25
- 52 Week High
- KTF $9.12
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- KTF 21.65
- DSGN 52.38
- Support Level
- KTF $9.95
- DSGN $5.55
- Resistance Level
- KTF $10.10
- DSGN $6.45
- Average True Range (ATR)
- KTF 0.09
- DSGN 0.56
- MACD
- KTF -0.06
- DSGN -0.04
- Stochastic Oscillator
- KTF 12.50
- DSGN 57.67
About KTF DWS Municipal Income Trust
DWS Municipal Income Trust is a closed-end, diversified investment management company. The investment objective is to provide high current income exempt from federal income tax by investing in a diversified portfolio of investment-grade tax-exempt securities. Its products include ETFs, Mutual Funds, Closed-End-Funds, Money Market Funds, and others.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.